Ki67与HER2在乳腺癌中相对预后价值研究
发布时间：2019-05-19 11:51
【摘要】：第一部分Ki67与HER2在人乳腺癌细胞系的差异表达研究目的：研究Ki67与HER2在人乳腺癌细胞系MCF-7 和 MDA-MB-231的差异表达,探讨其表达情况与乳腺癌细胞侵袭转移能力的相关性。方法：应用qPCR、Western Blot方法检测一对来源相同、侵袭转移能力不同的人乳腺癌细胞系MCF-7和MDA-MB-231中Ki67与HER2的mRNA和蛋白表达量,分析其差异表达与乳腺癌细胞侵袭转移能力的关系。结果：qPCR结果显示,Ki67 mRNA相对含量在具有高侵袭转移能力的MDA-MB-231细胞中约为低侵袭转移能力的MCF-7细胞中的3.31倍,其差异具有统计学意义(P0.01)；HER2 mRNA相对含量在具有高侵袭转移能力的MDA-MB-231细胞中约为低侵袭转移能力的MCF-7细胞中的1.79倍(P0.05)；Ki67 mRNA在两种细胞的含量差异大于HER2 mRNA在两种细胞的含量差异(3.31 vs.1.79)。Western Blot结果显示,Ki67与HER2蛋白在具有高侵袭转移能力的MDA-MB-231细胞中的表达均高于在低侵袭转移能力的MCF-7细胞中的表达与qPCR结果一致。结论：Ki67与HER2过表达与乳腺癌细胞的侵袭转移能力有一定相关性。第二部分量子点标记双分子探针技术研究乳腺癌中Ki67与HER2协同表达的预后价值目的：研究乳腺癌组织中Ki67与HER2协同表达情况,探寻两者在乳腺癌中的预后价值。方法：应用量子点标记双分子探针技术同时原位标记乳腺癌组织中Ki67和HER2,并用多光谱分析软件定量Ki67和HER2的表达,分析两者协同表达与乳腺癌患者8年无病生存(8-Disease free survival,8-DFS)的关系。结果：Ki67在癌细胞核上表达,标记成红色荧光,HER2在癌细胞膜上表达,标记成绿色荧光,两者对比明显,易于定量分析。Ki67与HER2表达量均与乳腺癌8-DFS呈负相关(P0.05)。中位8-DFS在高Ki67高HER2亚组明显短于低Ki67高HER2亚组(11.7 vs.60.1月,P0.05)；在高Ki67低HER2亚组短于低Ki67低HER2亚组(16.4vs.96.0月,P0.01)；在高Ki67高HER2亚组明显短于低Ki67低HER2亚组(11.7vs.96.0月,P0.01)；在高Ki67低HER2亚组与高Ki67高HER2亚组的差异无统计学意义(11.7vs.16.4月,P=0.586)。多因素分析显示,两者影响预后的权重不同,Ki67影响预后的风险比(Hazard ratio, HR)大约是HER2的3倍(HR 4.493 vs.1.481).结论：量子点标记探针技术有助于定量分析HER2和Ki67在乳腺癌中的协同表达,Ki67对乳腺癌预后不良的影响权重可能高于HER2。
[Abstract]:Part 1 differential expression of Ki67 and HER2 in human breast cancer cell line objective: to study the differential expression of Ki67 and HER2 in human breast cancer cell line MCF-7 and MDA-MB-231, and to explore the correlation between the expression of Ki67 and MDA-MB-231 and the ability of invasion and metastasis of breast cancer cell line. Methods: qPCR,Western Blot was used to detect the mRNA and protein expression of Ki67 and HER2 in a pair of human breast cancer cell lines MCF-7 and MDA-MB-231 with the same origin and different ability of invasion and metastasis. To analyze the relationship between the differential expression of breast cancer cells and the ability of invasion and metastasis of breast cancer cells. Results: the results of qPCR showed that the relative content of Ki67 mRNA in MDA-MB-231 cells with high invasion and metastasis ability was about 3.31 times higher than that in MCF-7 cells with low invasion and metastasis ability, and the difference was statistically significant (P 0.01). The relative content of HER2 mRNA in MDA-MB-231 cells with high invasion and metastasis ability was about 1.79 times higher than that in MCF-7 cells with low invasion and metastasis ability (P 0.05). The difference of Ki67 mRNA content between the two kinds of cells was greater than that of HER2 mRNA in the two kinds of cells (3.31 vs.1.79). Western Blot results showed that, The expression of Ki67 and HER2 protein in MDA-MB-231 cells with high invasion and metastasis ability was higher than that in MCF-7 cells with low invasion and metastasis ability, which was consistent with qPCR results. Conclusion: the overexpression of Ki67 and HER2 is related to the invasion and metastasis of breast cancer cells. The second part is to study the prognostic value of co-expression of Ki67 and HER2 in breast cancer by quantum dot labeling bimolecule probe. Objective: to study the co-expression of Ki67 and HER2 in breast cancer and to explore their prognostic value in breast cancer. Methods: quantum dot labeling bilayer probe technique was used to label Ki67 and HER2, in situ at the same time, and the expression of Ki67 and HER2 was quantified by multi-spectral analysis software. To analyze the relationship between the co-expression of the two and the disease-free survival (8-Disease free survival,8-DFS) of breast cancer patients for 8 years. Results: Ki67 was expressed in the nucleus of cancer, marked with red fluorescence, and HER2 was expressed on the cell membrane of cancer, marked with green fluorescence. Ki67 and HER2 expression were negatively correlated with 8-DFS in breast cancer (P 0.05). The expression of Ki67 and Ki67 was negatively correlated with the expression of Ki67 and Ki67 in breast cancer. The median 8-DFS in high Ki67 and high HER2 subgroup was significantly shorter than that in low Ki67 and high HER2 subgroup (11.7 vs.60.1 month, P 0.05), and in high Ki67 and low HER2 subgroup was shorter than that in low Ki67 and low HER2 subgroup (16.4vs.96.0 month, P 0.01). In high Ki67 and high HER2 subgroup, it was significantly shorter than that in low Ki67 and low HER2 subgroup (11.7vs.96.0 month, P 0.01), but there was no significant difference between high Ki67 and low HER2 subgroup and high Ki67 and high HER2 subgroup (11.7vs.16.4 month, P 鈮，
本文编号：2480703
[Abstract]:Part 1 differential expression of Ki67 and HER2 in human breast cancer cell line objective: to study the differential expression of Ki67 and HER2 in human breast cancer cell line MCF-7 and MDA-MB-231, and to explore the correlation between the expression of Ki67 and MDA-MB-231 and the ability of invasion and metastasis of breast cancer cell line. Methods: qPCR,Western Blot was used to detect the mRNA and protein expression of Ki67 and HER2 in a pair of human breast cancer cell lines MCF-7 and MDA-MB-231 with the same origin and different ability of invasion and metastasis. To analyze the relationship between the differential expression of breast cancer cells and the ability of invasion and metastasis of breast cancer cells. Results: the results of qPCR showed that the relative content of Ki67 mRNA in MDA-MB-231 cells with high invasion and metastasis ability was about 3.31 times higher than that in MCF-7 cells with low invasion and metastasis ability, and the difference was statistically significant (P 0.01). The relative content of HER2 mRNA in MDA-MB-231 cells with high invasion and metastasis ability was about 1.79 times higher than that in MCF-7 cells with low invasion and metastasis ability (P 0.05). The difference of Ki67 mRNA content between the two kinds of cells was greater than that of HER2 mRNA in the two kinds of cells (3.31 vs.1.79). Western Blot results showed that, The expression of Ki67 and HER2 protein in MDA-MB-231 cells with high invasion and metastasis ability was higher than that in MCF-7 cells with low invasion and metastasis ability, which was consistent with qPCR results. Conclusion: the overexpression of Ki67 and HER2 is related to the invasion and metastasis of breast cancer cells. The second part is to study the prognostic value of co-expression of Ki67 and HER2 in breast cancer by quantum dot labeling bimolecule probe. Objective: to study the co-expression of Ki67 and HER2 in breast cancer and to explore their prognostic value in breast cancer. Methods: quantum dot labeling bilayer probe technique was used to label Ki67 and HER2, in situ at the same time, and the expression of Ki67 and HER2 was quantified by multi-spectral analysis software. To analyze the relationship between the co-expression of the two and the disease-free survival (8-Disease free survival,8-DFS) of breast cancer patients for 8 years. Results: Ki67 was expressed in the nucleus of cancer, marked with red fluorescence, and HER2 was expressed on the cell membrane of cancer, marked with green fluorescence. Ki67 and HER2 expression were negatively correlated with 8-DFS in breast cancer (P 0.05). The expression of Ki67 and Ki67 was negatively correlated with the expression of Ki67 and Ki67 in breast cancer. The median 8-DFS in high Ki67 and high HER2 subgroup was significantly shorter than that in low Ki67 and high HER2 subgroup (11.7 vs.60.1 month, P 0.05), and in high Ki67 and low HER2 subgroup was shorter than that in low Ki67 and low HER2 subgroup (16.4vs.96.0 month, P 0.01). In high Ki67 and high HER2 subgroup, it was significantly shorter than that in low Ki67 and low HER2 subgroup (11.7vs.96.0 month, P 0.01), but there was no significant difference between high Ki67 and low HER2 subgroup and high Ki67 and high HER2 subgroup (11.7vs.16.4 month, P 鈮，
本文编号：2480703
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2480703.html
